Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Aug 01, 2026

On 24 May 2024, after roughly a quarter-century of negotiation, the Member States of the World Intellectual Property Organisation adopted, by consensus

WIPO GRATK Treaty: India Helped Write and Would Not Sign
News & Updates, Thought Leadership
Jul 17, 2026

First published by Lexology. Authors: Sandhya Singh and Sampada Kapoor Modern sport is no longer merely an athletic competition; it is a multi-billion-dollar

Managing Ambush Marketing: Legal and Commercial Perspectives
News & Updates, Thought Leadership
Jul 16, 2026

First published by IP Stars. Authors: Safir Anand and Sehr Anand In a digital landscape where the internet never forgets, an individual’s past can

The Right Not to Be Published: Inside the Delhi High Court’s Landmark ‘Right to Be Forgotten’ Judgment
News & Updates, Thought Leadership
Jul 14, 2026

First published by Lexology. Authors: Lakshmidevi Somanath and Kanishka Vaish I. The Quiet Trend of Strong Evidence Engineering Anyone who has appeared

Evidence Engineering in IP Litigation